Why is Glenmark Pharma falling/rising?

Recent Price Movement and Market Outperformance

The stock has demonstrated notable momentum, gaining 4.53% over the past week compared to the Sensex’s modest 0.50% rise. Over the last month, Glenmark outpaced the benchmark with a 5.77% increase against Sensex’s 1.66%. Year-to-date, the stock has surged 19.56%, doubling the Sensex’s 9.56% gain. This outperformance extends over longer horizons as well, with a remarkable 26.52% return in the past year compared to the Sensex’s 7.01%, and an extraordinary 350.89% gain over three years versus the benchmark’s 37.43%.

On the day in question, Glenmark’s shares touched an intraday high of ₹1,927.10, marking a 2.43% increase. The stock has been on a two-day winning streak, delivering a cumulative 4.48% return in this period. It also outperformed its sector by 1.08%, signalling robust relative strength. Despite this, investor participation has slightly waned, with delivery volumes on 25 Nov falling 21.14% below the five-day average, though liquidity remains sufficient for sizeable trades.

Strong Financial Performance Underpinning the Rally

The primary driver behind Glenmark’s stock appreciation is its outstanding financial results declared in September 2025. The company reported a staggering 1,199.62% growth in net profit, signalling a dramatic turnaround and operational excellence. This surge is supported by a return on capital employed (ROCE) of 35.65% for the half-year, which is among the highest in its peer group. Additionally, the operating profit to interest ratio stands at an impressive 35.50 times, highlighting the company’s strong ability to cover interest expenses comfortably.

Glenmark’s cash and cash equivalents have also reached a peak of ₹2,690.24 crores, providing ample liquidity and financial flexibility. The company’s low debt-to-EBITDA ratio of 0.89 times further underscores its prudent capital structure and capacity to service debt efficiently, which is a key consideration for investors seeking stability alongside growth.

Valuation and Institutional Confidence

Despite its strong performance, Glenmark trades at a price-to-book value of 5.7, which is considered attractive relative to its historical peer valuations. The company’s return on equity (ROE) of 23.5% reflects efficient utilisation of shareholder funds. Over the past year, while the stock has delivered a 26.52% return, its profits have surged by 554.2%, resulting in a PEG ratio of zero, indicating that the stock’s price growth is well supported by earnings expansion.

Institutional investors hold a significant 39.38% stake in Glenmark, and their confidence appears to be growing, with holdings increasing by 1.08% over the previous quarter. This institutional backing often signals strong fundamental support and can provide stability to the stock price amid market fluctuations.

Consistent Long-Term Outperformance

Glenmark’s stock has consistently outperformed the broader market and its sector peers over multiple time frames. Its three-year return of 350.89% dwarfs the Sensex’s 37.43%, and its five-year gain of 310.35% significantly exceeds the benchmark’s 93.43%. This track record of sustained growth and value creation has helped build investor trust and contributed to the current positive sentiment.

While the stock is trading above its 5-day, 20-day, 50-day, and 200-day moving averages, it remains below the 100-day moving average, suggesting some room for further technical upside. The combination of strong fundamentals, attractive valuation metrics, and institutional support explains why Glenmark Pharmaceuticals’ share price is rising steadily.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →